相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
High-Resolution Melting Analysis as a Sensitive Prescreening Diagnostic Tool to Detect KRAS, BRAF, PIK3CA, and AKT1 Mutations in Formalin-Fixed, Paraffin-Embedded Tissues
Jasmin Teresa Ney et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
Young Seok Ju et al.
GENOME RESEARCH (2012)
The transcriptional landscape and mutational profile of lung adenocarcinoma
Jeong-Sun Seo et al.
GENOME RESEARCH (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
Hans-Ulrich Schildhaus et al.
MODERN PATHOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Absolute quantification of somatic DNA alterations in human cancer
Scott L. Carter et al.
NATURE BIOTECHNOLOGY (2012)
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
Charles M. Rudin et al.
NATURE GENETICS (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Doron Lipson et al.
NATURE MEDICINE (2012)
KIF5B-RET fusions in lung adenocarcinoma
Takashi Kohno et al.
NATURE MEDICINE (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation
Matthew D. Wilkerson et al.
PLOS ONE (2012)
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
Heidi Greulich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib
Banibrata Sen et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Kimberly Brown Dahlman et al.
CANCER DISCOVERY (2012)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
Natasha Rekhtman et al.
MODERN PATHOLOGY (2011)
New driver mutations in non-small-cell lung cancer
William Pao et al.
LANCET ONCOLOGY (2011)
Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens
Silvia Querings et al.
PLOS ONE (2011)
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Amit Dutt et al.
PLOS ONE (2011)
Mutations in the DDR2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer
Peter S. Hammerman et al.
CANCER DISCOVERY (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types
Matthew D. Wilkerson et al.
CLINICAL CANCER RESEARCH (2010)
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
Yoo Ri Kim et al.
JOURNAL OF PATHOLOGY (2010)
Advances in understanding cancer genomes through second-generation sequencing
Matthew Meyerson et al.
NATURE REVIEWS GENETICS (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis
Deepti Malhotra et al.
NUCLEIC ACIDS RESEARCH (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis
Ronglai Shen et al.
BIOINFORMATICS (2009)
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
Adam J. Bass et al.
NATURE GENETICS (2009)
Large Cell Carcinoma of the Lung An Endangered Species?
Javier Pardo et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2009)
Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth
Tsutonm Ohta et al.
CANCER RESEARCH (2008)
Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma
Reika Iwakawa et al.
CLINICAL CANCER RESEARCH (2008)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy
Tatsuhiro Shibata et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
EML4-ALK fusion lung cancer:: A rare acquired event
Sven Perner et al.
NEOPLASIA (2008)
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir et al.
NATURE (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Patterns of somatic mutation in human cancer genomes
Christopher Greenman et al.
NATURE (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
TMPRSS2:: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
Sven Perner et al.
CANCER RESEARCH (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
No evidence of somatic FGFR3 mutation in various types of carcinoma
M Karoui et al.
ONCOGENE (2001)
分享论文
